干扰素驱动基因特征作为幼年特发性关节炎甲氨蝶呤治疗反应预测因子的识别与验证
研究对非全身型幼年特发性关节炎(JIA)患儿在甲氨蝶呤(MTX)治疗前的外周血CD4+、CD8+、CD14+、CD19+细胞及外周血单个核细胞进行RNA测序,在发现队列(n=97)和2个验证队列(n=26和n=47)中分析基因表达与6个月治疗反应的关系。结果显示,基线干扰素α(I型)或γ(II型)驱动基因表达与3个独立JIA队列的6个月治疗反应相关,基线干扰素刺激基因表达较高的患儿更可能成为良好反应者。与成人类风湿关节炎数据(n=240)比较提示,外周血单个核细胞与全血基因表达关联存在差异。
要点
- 在3个独立JIA队列中,基线I型或II型干扰素驱动基因表达与MTX治疗6个月反应相关。
- 基线干扰素刺激基因表达较高的患儿更可能成为MTX良好反应者。
- 与成人RA数据比较,外周血单个核细胞与全血基因表达关联存在差异。
核心结论
- 在JIA患儿中,高干扰素驱动基因特征与较好的MTX治疗反应相关,优于低干扰素驱动基因特征。
研究设计与样本
- 对非全身型JIA患儿在MTX治疗前分选CD4+、CD8+、CD14+、CD19+细胞及外周血单个核细胞进行RNA测序,发现队列n=97,2个验证队列n=26和n=47。
- 临床数据在基线(时间点1)和治疗6个月(时间点2)记录,使用limma-voom、基因集富集分析和新型51基因评分分析特定细胞类型基因表达与治疗反应的关联。
- 平行分析使用治疗前基因表达数据在成人类风湿关节炎数据(n=240)中进行。
主要发现
- 在3个独立JIA队列中,基线干扰素α(I型)或γ(II型)驱动基因表达与6个月治疗反应相关。
- 关联方向表明,MTX治疗前干扰素刺激基因基线表达较高的患儿更可能成为良好反应者。
- 与成人RA比较表明,外周血单个核细胞与全血基因表达关联与治疗反应的关系存在差异。
关键数值与推荐
- 发现队列n=97,验证队列n=26和n=47,均为非全身型JIA患者。
- 成人RA数据n=240用于平行分析。
- 使用新型51基因评分评估治疗反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To identify and validate gene expression biomarkers of response to methotrexate (MTX) treatment in peripheral blood of children with juvenile idiopathic arthritis (JIA) measured before starting MTX treatment. METHODS: RNA sequencing was performed on sorted CD4+, CD8+, CD14+, and CD19+ cells, as well as peripheral blood mononuclear cells (PBMC) taken pre-treatment in a discovery cohort (n = 97) and 2 validation cohorts (n = 26 and n = 47, respectively) of patients with non-systemic JIA. Clinical data were recorded at baseline (timepoint 1) prior to treatment and 6 months (timepoint 2) of MTX treatment. Analysis tested the association of gene expression in specific cell types with treatment response using limma-voom, gene set enrichment analysis, and a novel 51-gene score against response to treatment. Parallel analysis, also using pre-treatment gene expression data, was performed in adult rheumatoid arthritis (RA) data (n = 240). RESULTS: In patients with JIA, the baseline expression of genes driven by interferon (IFN) alpha (type-I) or gamma (type-II) was associated with response to treatment at 6 months in 3 independent JIA cohorts. The direction of the association indicated that children with higher baseline expression of IFN-stimulated genes prior to MTX were more likely to be good responders. Comparison with adult RA indicated differences between PBMC and whole blood gene expression associations with response. CONCLUSIONS: In children with JIA, a high IFN-driven gene signature is associated with a better response to MTX than those with a low IFN-driven gene signature. These data could pave the way to clinically validated tools to identify those most likely to require medications in addition to MTX to control inflammation.
引用
- Kartawinata M, Lin WY, Jebson B, et al. Identification and validation of interferon-driven gene signature as a predictor of response to methotrexate in juvenile idiopathic arthritis. Ann Rheum Dis. 2025. PMID: 40681434. doi:10.1016/j.ard.2025.03.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。